Publication date: December 2026 Source: ESMO Gastrointestinal Oncology, Volume 14 Author(s): J.W. Lee, P.E. Oberstein, J.D. Goldberg, M. Jia, D. Becker, D. Siolas, N. Beri, T. Ryan, P. Kozuch, B. Levinson, L.P. Leichman, D.J. Cohen
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826001202?dgcid=rss_sd_all
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826001202?dgcid=rss_sd_all
“Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy.” ESMO Gastrointestinal Oncology.
@article{article44595,
title = {Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826001202?dgcid=rss_sd_all}
}